Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for AUROPHARMA
Revenue projections for AUROPHARMA

AUROPHARMA's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 14.710088
debtToEquity 25.310000
earningsGrowth -0.095000
revenueGrowth 0.040000
grossMargins 0.588050
operatingMargins 0.152220
trailingEps 58.260000
forwardEps 62.290000

AUROPHARMA's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
AUROPHARMA's low Debt-to-Equity ratio shows that the company isn't heavily reliant on debt for financing. This implies a conservative approach to leveraging, reducing financial risk and demonstrating a solid financial foundation, which can enhance investor confidence in the company's long-term stability.
AUROPHARMA's low earnings and revenue growth suggest that its profits could shrink. This points to a potential downturn in the company's financial outlook and may indicate challenges in maintaining profitability.
Aurobindo Pharma Limited's negative gross and operating margins highlight that the company is incurring losses, unable to generate profit from production or operations. This could be a sign of rising costs or declining revenues, impacting its financial outlook.
Aurobindo Pharma Limited's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for Aurobindo Pharma Limited's financial growth.

Price projections:

Price projections for AUROPHARMA
Price projections for AUROPHARMA

AUROPHARMA's price has continuously remained near the lower end of analysts' projections, indicating that it may be facing challenges in meeting market expectations. This trend raises concerns about the company's future growth trajectory.

Recommendation changes over time:

Recommendations trend for AUROPHARMA
Recommendations trend for AUROPHARMA


AUROPHARMA has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view AUROPHARMA as a stable option to park their money and potentially benefit from the company's continued growth and profitability.